Abstract Details

Title Investigating synaptic changes in Essential Tremor with PET Imaging

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-005

Objective To utilize positron emission tomography (PET) imaging with the synaptic density tracer [¹¹C] UCB-J to characterize the distribution in the cerebellum and other brain areas in essential tremor (ET) compared to healthy controls (HC).

Background

Numerous lines of evidence point to a cerebellar origins of ET, with a number of studies pointing to Purkinje cell loss. Studying potential markers of cell loss in vivo would be of great value. [¹¹C] UCB-J has been found to be an excellent tracer for quantitative imaging of synaptic vesicle glycoprotein 2A (SV2A), a marker of synaptic density, in the human brain. This tracer has not been used to study the ET brain.

Design/Methods Six individuals with ET with a mean age (SD) of 65 (10); three males), and sixteen demographically matched healthy comparison controls (HC; 63 (9); six males) participated in an [ ¹¹C] UCB-J PET scan. Binding potential value (BP_ND: binding potential of available receptors) was the primary outcome measure and using the centrum semiovale as the reference region. Muller Gartner partial volume correction (PVC) was applied to control for possible volumetric differences. T-tests were calculated for between group differences, and p values were uncorrected for multiple comparisons given the exploratory nature.

Results

We observed significantly lower synaptic availability in ET compared to HC in the cerebellum (-11%, p=0.04), right cerebellum (-11%, p=0.03), vermis (-12%, p=0.04), motor cortex (-21%, p=0.001), and supplementary motor cortex (-20%, p=0.006).

Conclusions This in vivo investigation with [¹¹C] UCB-J PET in ET is the first sample to date (to our knowledge) and found preliminary evidence of lower synaptic availability in key brain areas. Additional data analysis is ongoing, such as applying Iterative-Yang PVC, correlating synaptic changes with clinical scores, and exploring network-based analyses.

Authors/Disclosures
Yanghong Yang, MD PRESENTER	Dr. Yang has nothing to disclose.
Mika Naganawa	Mika Naganawa has nothing to disclose.
Nora Hernandez	No disclosure on file
	No disclosure on file
Nabeel Nabulsi	Nabeel Nabulsi has nothing to disclose.
Yiyun Huang	Yiyun Huang has nothing to disclose.
	No disclosure on file
David Matuskey, MD (Yale University)	Dr. Matuskey has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Eleisver. The institution of Dr. Matuskey has received research support from Abbvie.
Elan D. Louis, MD, MS, FAAN (University of Texas Southwestern Medical Center)	Dr. Louis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwer - Merritt's Textbook of Neurology. Dr. Louis has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Legal Firm. The institution of Dr. Louis has received research support from National Institutes of Health. Dr. Louis has received publishing royalties from a publication relating to health care. Dr. Louis has a non-compensated relationship as a Board of Directors with International Essential Tremor Foundation that is relevant to AAN interests or activities. Dr. Louis has a non-compensated relationship as a Medical Advisory Board with HopeNET that is relevant to AAN interests or activities.

��ɫ��

��ɫ��